On 1.8 Million Shares Ovid Therapeutics (OVID) Pops Over 40%

Just like Monday, today is the day of surging healthcare stocks of Viveve, Ocugen, and Ovid that jumps from $6.37 to $8.80 in premarket on over 1.8 million shares of daily volume.

NASDAQ: OVID has grown since March and became one of the most demanded biotech stocks during the pandemic and economic crisis. Even after the COVID-19 goes away Ovid will surge further unless failed tests are leaked.

16.79% fall on Monday actually was a hint for the instant growth of today. Until the end of trading, there is plenty of time, speculative traders may consider OVID to their active portfolios while the stock is cheap.

Michael Rowels

Weekend Contributor. Writing for business and finance publishers has become his passion over the last decades after he completed a master's degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.